

BUY**TP: Rs 144 | ▲ 16%****DCB BANK**

| Banking

| 28 September 2023

Improving prospects; BUY

- **Expect a strong 18% credit CAGR over FY23-FY25 (1.4x industry growth), supported by a better portfolio mix**
- **Margin to sustain at current level with both operational and credit cost forecast to gradually soften; expect a PPOP CAGR of 24%**
- **Improved return ratios along with growth can fetch higher valuations; we assume coverage with BUY and a TP of Rs 144 (0.8x FY25E ABV)**

Ajit Agrawal

research@bobcaps.in

Targeting 2x growth in balance sheet: Muted SME/MSME disbursal along with lower participation in e-platform TReDS moderated growth in DCBB's advances to 19% YoY in Q1FY24. Going forward, we expect network expansion and a sharp focus on retail products such as mortgage, SME/MSME, gold loans, and AIB to support an 18% credit CAGR over FY23-FY25 (along with a 17% deposit CAGR). Management is confident of growth and aims to double the balance sheet in 3-4 years.

Margin to improve...: The recent NIM contraction (31bps QoQ in Q1FY24) was mainly due to a change in portfolio mix towards corporate loans and a higher cost of funds. We believe a majority of the increase in cost of funds is factored in and expect a recovery in AIB, mortgage and TReDS to help the bank maintain NIM at 3.72%/3.65% over FY24/FY25 – broadly in line with its target range of 3.7-3.75%.

...but C/I to remain high: On the operational front, the bank has invested heavily in network and human resources, adding 75 branches and 3,473 employees during FY22-FY23 vs. 19 branches and 298 employees over FY20-FY21. This has led to higher C/I ratios of 64%/63% in Q1FY24/FY23 vs. 48.5% in FY21. We expect sticky operating cost to keep the C/I ratio high at 62% in FY24 (and 59% in FY25).

Asset stress expected to ease: As most of the loan book emerged from moratorium in recent months, slippages were elevated at 4% of advances during Q1FY24. Management is confident of limiting slippages and expects asset quality to improve hereon. We model for controlled slippages of 3.6% in both FY24 and FY25, aiding improvement in GNPA/NNPA to 2.3%/0.9% over FY25. The bank's restructured book stood at 4% of loans in Q1, wherein it already has provisions of 14-15%. We pencil in credit cost of 54bps/60bps in FY24/FY25 vs. 50bps in FY23.

BUY, TP Rs 144: Baking in healthy growth, sustainable margins and improving asset quality, we expect DCBB to clock ROA/ROE of 1%/13% in FY25 vs. 0.96%/10.8% in FY23. However, sustainability of business growth would be key to watch. The stock is trading at 0.7x FY25E ABV. We assume coverage with BUY, valuing DCBB at 0.8x FY25E ABV for a TP of Rs 144, based on the Gordon Growth Model.

Key changes

| Target | Rating |
|--------|--------|
| ▲ | ▲ |


| | |
|------------------|----------------|
| Ticker/Price | DCBB IN/Rs 125 |
| Market cap | US\$ 472.0mn |
| Free float | 85% |
| 3M ADV | US\$ 2.7mn |
| 52wk high/low | Rs 141/Rs 96 |
| Promoter/FPI/DII | 15%/12%/40% |

Source: NSE | Price as of 27 Sep 2023

Key financials

| Y/E 31 Mar | FY23A | FY24E | FY25E |
|-------------------------|--------|--------|--------|
| Net interest income | 17,170 | 20,026 | 23,175 |
| NII growth (%) | 26.5 | 16.6 | 15.7 |
| Adj. net profit (Rs mn) | 4,656 | 5,631 | 7,021 |
| EPS (Rs) | 15.0 | 18.1 | 22.5 |
| Consensus EPS (Rs) | 15.0 | 17.3 | 20.8 |
| P/E (x) | 8.3 | 6.9 | 5.5 |
| P/BV (x) | 0.8 | 0.8 | 0.7 |
| ROA (%) | 1.0 | 1.0 | 1.0 |
| ROE (%) | 10.8 | 11.7 | 13.0 |

Source: Company, Bloomberg, BOBCAPS Research

Stock performance

Source: NSE



Fig 1 – Loan book trend

| (Rs mn) | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | YoY (%) | QoQ (%) |
|--------------------|----------------|----------------|----------------|----------------|----------------|-------------|------------|
| AIB | 62,609 | 67,589 | 72,523 | 80,107 | 82,300 | 31.4 | 2.7 |
| Mortgage | 125,219 | 133,927 | 140,761 | 150,588 | 158,569 | 26.6 | 5.3 |
| Corporate banking | 29,814 | 32,543 | 32,965 | 27,161 | 28,734 | (3.6) | 5.8 |
| Gold Loan | 14,907 | 15,020 | 13,845 | 13,065 | 12,771 | (14.3) | (2.3) |
| Commercial vehicle | 8,944 | 6,884 | 5,604 | 4,813 | 3,902 | (56.4) | (18.9) |
| SME+MSME | 26,833 | 29,727 | 29,998 | 28,880 | 23,768 | (11.4) | (17.7) |
| Co-Lending | 17,888 | 15,646 | 21,098 | 24,754 | 27,670 | 54.7 | 11.8 |
| Others | 11,926 | 11,578 | 12,856 | 14,440 | 17,028 | 42.8 | 17.9 |
| Total | 298,140 | 312,914 | 329,650 | 343,807 | 354,740 | 19.0 | 3.2 |

Source: Company, BOBCAPS Research

Fig 2 – Loan book distribution

| Segment (%) | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | YoY (bps) | QoQ (bps) |
|--------------------|--------|--------|--------|--------|--------|-----------|-----------|
| AIB | 21.0 | 21.6 | 22.0 | 23.3 | 23.2 | 220 | (10) |
| Mortgage | 42.0 | 42.8 | 42.7 | 43.8 | 44.7 | 270 | 90 |
| Corporate banking | 10.0 | 10.4 | 10.0 | 7.9 | 8.1 | (190) | 20 |
| Gold Loan | 5.0 | 4.8 | 4.2 | 3.8 | 3.6 | (140) | (20) |
| Commercial vehicle | 3.0 | 2.2 | 1.7 | 1.4 | 1.1 | (190) | (30) |
| SME+MSME | 9.0 | 9.5 | 9.1 | 8.4 | 6.7 | (230) | (170) |
| Co-Lending | 6.0 | 5.0 | 6.4 | 7.2 | 7.8 | 180 | 60 |
| Others | 4.0 | 3.7 | 3.9 | 4.2 | 4.8 | 80 | 60 |

Source: Company, BOBCAPS Research

Fig 3 – Deposit trend


| (Rs mn) | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | YoY (%) | QoQ (%) |
|-----------------------|----------------|----------------|----------------|----------------|----------------|-------------|------------|
| CASA | 100,240 | 108,460 | 109,110 | 108,960 | 111,670 | 11.4 | 2.5 |
| Resident | 195,445 | 201,861 | 224,757 | 238,799 | 251,870 | 28.9 | 5.5 |
| Non-Resident | 32,574 | 37,082 | 38,603 | 40,963 | 41,395 | 27.1 | 1.1 |
| Inter-Bank | 22,551 | 22,197 | 22,590 | 23,668 | 25,155 | 11.5 | 6.3 |
| Term Deposits | 250,570 | 261,140 | 285,950 | 303,430 | 318,420 | 27.1 | 4.9 |
| Total Deposits | 350,810 | 369,600 | 395,060 | 412,390 | 430,090 | 22.6 | 4.3 |

Source: Company, BOBCAPS Research


Fig 4 – Deposit distribution

| (%) | Q1FY23 | Q2FY23 | Q3FY23 | Q4FY23 | Q1FY24 | YoY (bps) | QoQ (bps) |
|-----------------------|--------------|--------------|--------------|--------------|--------------|-----------|-----------|
| CASA | 28.6 | 29.3 | 27.6 | 26.4 | 26.0 | (261) | (46) |
| Resident | 55.7 | 54.6 | 56.9 | 57.9 | 58.6 | 285 | 66 |
| Non-Resident | 9.3 | 10.0 | 9.8 | 9.9 | 9.6 | 34 | (31) |
| Inter-Bank | 6.4 | 6.0 | 5.7 | 5.7 | 5.8 | (58) | 11 |
| Term Deposits | 71.4 | 70.7 | 72.4 | 73.6 | 74.0 | 261 | 46 |
| Total Deposits | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 0 | 0 |


Source: Company, BOBCAPS Research

Fig 5 – Expect a 18% credit CAGR for FY23-FY25E...


Source: Company, BOBCAPS Research

Fig 6 – ...and 17% deposit CAGR


Source: Company, BOBCAPS Research

Fig 7 – Asset growth to remain healthy


Source: Company, BOBCAPS Research

Fig 8 – CASA ratio to hold at 26% levels


Source: Company, BOBCAPS Research

Fig 9 – Cost of funds on the rise


Source: Company, BOBCAPS Research

Fig 10 – Focus on granular retail business to support NIM


Source: Company, BOBCAPS Research

Fig 11 – Opex to normalise


Source: Company, BOBCAPS Research

Fig 12 – PPOP growth to come off a low base


Source: Company, BOBCAPS Research

Fig 13 – Asset quality improving


Source: Company, BOBCAPS Research

Fig 14 – Credit cost to remain stable


Source: Company, BOBCAPS Research

Fig 15 – Expect a 23% PAT CAGR


Source: Company, BOBCAPS Research

Fig 16 – Return ratios improving but still below peers

Source: Company, BOBCAPS Research

Fig 17 – Stable RWA-to-asset ratio to aid CAR

Source: Company, BOBCAPS Research

Fig 18 – Well capitalised to fund credit demand

Source: Company, BOBCAPS Research

Valuation methodology

Key forecasts

DCBB has invested heavily in network and human resources, adding 75 branches and 3,473 employees during FY22-FY23 vs. just 19 branches and 298 employees over FY20-FY21. Following this expansion, management has set itself a medium-term (3-4-year) target of doubling the balance sheet. We expect growing market penetration together with a focus on the mortgage, agri & inclusive banking (AIB), gold loan and SME/MSME segments to support a credit CAGR of 18% over FY23-FY25. Deposits are estimated to log a 17% CAGR for the same period (vs. expected industry growth of 13-14% for both deposit and credit).

We model for an NII CAGR of 16.2% and higher 24% growth in other income backed by core fees. Management expects to register NIM in the range of 3.7-3.75% during FY24 and has attributed the 31bps QoQ contraction during Q1FY24 to a temporary spike in competitive intensity in TReDS business. The bank's focus on high yielding business is likely to support margins, though management expects some pressure from deposit repricing. We believe a majority of the increase in cost of funds is factored in and expect a recovery in AIB, mortgage and TReDS to help the bank maintain NIM at 3.72%/3.65% over FY24/FY25.

The aggressive branch expansion over the last two years pushed DCBB's C/I ratio up to 64%/63% in Q1FY24/FY23 vs. 48.5% in FY21. Management is guiding for slower additions of 25-30 branches ahead and expects leverage from higher volumes to normalise operating cost. However, we believe operating cost will remain sticky as the bank's core focus lies in the retail business. We thus model for a CI ratio of 59% by FY25 while the bank expects to approach 55% over the next 3-4 years. Baking in sticky operational costs, PPOP is forecast to log a 24% CAGR over FY23-FY25 on a lower base.

DCBB's asset quality has witnessed substantial improvement in FY23 with controlled slippages and increased upgrades and recovery. Q1FY24, however, saw some deterioration as the moratorium benefit on its mortgage portfolio came to an end. Management is confident of limiting slippages and expects asset quality to improve hereon. We model for slippages of 3.6% in both FY24 and FY25, aiding improvement in GNPA/NNPA to 2.3%/0.9% over FY25 with PCR of 65%.

The bank's restructured book stood at 4% of loans in Q1, but management has indicated that provisions of 14-15% are in place, which provide some cushion towards credit cost. We pencil in credit cost of 54bps/60bps over FY24/FY25 vs. 50bps in FY23. The bank is well capitalised with CAR of 17.1% (tier-1 at 14.8%) as of Jun'23, and we estimate healthy levels of 14%/16% in FY24/FY25.

BUY, TP Rs 144

In our view, DCBB's recent network buildout and focus on high yielding segments such as AIB and SME/MSME could help the bank expand its balance sheet in line with guidance. We believe operational efficiency would improve, albeit gradually, and estimate ROA/ROE of 1%/13% in FY25 vs. 0.96%/11% in FY23. The stock is trading at 0.7x FY25E ABV. We assume coverage with a BUY rating, valuing DCBB at 0.8x FY25E ABV for a TP of Rs 144, based on the Gordon Growth Model.

Fig 19 – Key operational assumptions

| Parameter (%) | FY22 | FY23 | FY24E | FY25E |
|-----------------|--------|-------|-------|-------|
| Advances Growth | 12.1 | 18.2 | 18.0 | 17.5 |
| NII Growth | 5.5 | 26.5 | 16.6 | 15.7 |
| PPoP growth | (11.3) | (1.3) | 21.7 | 26.2 |
| PAT growth | (14.4) | 61.9 | 21.0 | 24.7 |
| NIM | 3.4 | 3.8 | 3.7 | 3.7 |
| GNPA | 4.2 | 3.2 | 2.6 | 2.3 |
| CAR | 18.9 | 17.6 | 16.4 | 15.9 |

Source: Company, BOBCAPS Research

Fig 20 – Key valuation assumptions: Gordon growth model

| Particulars | |
|---------------------------------------|------|
| Cost of equity (%) | 12.5 |
| Blended ROE (%) | 11.2 |
| Initial high growth period (yrs) | 10.0 |
| Payout ratio of high-growth phase (%) | 20.0 |
| Long-term growth (%) | 4 |
| Long term dividend payout ratio (%) | 60 |
| Justified P/BV Multiple (x) | 0.8 |

Source: Company, BOBCAPS Research

Key risks

- Inability of the bank to manage a higher cost of funds with faster deposit repricing would represent a key downside risk.

Sector recommendation snapshot

| Company | Ticker | Market Cap (US\$ bn) | Price (Rs) | Target (Rs) | Rating |
|---------------------|-----------|----------------------|------------|-------------|--------|
| Axis Bank | AXSB IN | 38.4 | 1,025 | 1,155 | BUY |
| DCB Bank | DCBB IN | 0.5 | 125 | 144 | BUY |
| Federal Bank | FB IN | 3.9 | 151 | 165 | BUY |
| HDFC Bank | HDFCB IN | 140.1 | 1,527 | 2,061 | BUY |
| ICICI Bank | ICICIB IN | 80.2 | 943 | 1,015 | HOLD |
| Indusind Bank | IIB IN | 13.6 | 1,436 | 1,755 | BUY |
| Kotak Mahindra Bank | KMB IN | 42.7 | 1,765 | 2,122 | HOLD |
| RBL Bank | RBK IN | 1.8 | 245 | 233 | HOLD |
| State Bank of India | SBIN IN | 64.1 | 590 | 729 | BUY |

Source: BOBCAPS Research, NSE | Price as of 27 Sep 2023

Glossary

| Glossary of Abbreviations | | | |
|---------------------------|---------------------------------------|-------------|---|
| AUCA | Advance Under Collection Account | LCR | Liquidity Coverage Ratio |
| AIB | Agri & Inclusive Banking | MCLR | Marginal Cost of Funds-based Lending Rate |
| ARC | Asset Reconstruction Company | MFI | Microfinance Institution |
| BRDS | Bills Rediscounting Scheme | MTM | Mark to Market |
| CASA | Current Account and Savings Account | NII | Net Interest Income |
| CAR | Capital Adequacy Ratio | NIM | Net Interest Margin |
| CET1 | Common Equity Tier 1 | NNPA | Net Non-Performing Assets |
| CD | Credit-Deposit Ratio | PCR | Provision Coverage Ratio |
| C/I | Cost-Income Ratio | PPOP | Pre-Provision Operating Profit |
| CRB | Commercial and Rural Banking | PSU | Public Sector Unit |
| EBLR | External Benchmark-based Lending Rate | RWA | Risk-weighted Assets |
| ECL | Expected Credit Loss | SLR | Statutory Liquidity Ratio |
| GNPA | Gross Non-Performing Assets | SMA | Special Mention Account |
| IBPC | Interbank Participation Certificate | SME | Small and Medium-sized Enterprises |
| LAP | Loans against Property | | |

Financials

Income Statement

| Y/E 31 Mar (Rs mn) | FY21A | FY22A | FY23A | FY24E | FY25E |
|---------------------|--------|--------|--------|--------|--------|
| Net interest income | 12,866 | 13,575 | 17,170 | 20,026 | 23,175 |
| NII growth (%) | 1.7 | 5.5 | 26.5 | 16.6 | 15.7 |
| Non-interest income | 4,585 | 4,520 | 4,094 | 5,163 | 6,273 |
| Total income | 17,451 | 18,095 | 21,264 | 25,189 | 29,449 |
| Operating expenses | 8,466 | 10,126 | 13,397 | 15,613 | 17,365 |
| PPOP | 8,985 | 7,970 | 7,867 | 9,576 | 12,084 |
| PPOP growth (%) | 19.3 | (11.3) | (1.3) | 21.7 | 26.2 |
| Provisions | 4,457 | 4,074 | 1,592 | 2,024 | 2,647 |
| PBT | 4,528 | 3,895 | 6,276 | 7,553 | 9,437 |
| Tax | 1,170 | 1,020 | 1,620 | 1,921 | 2,416 |
| Reported net profit | 3,358 | 2,875 | 4,656 | 5,631 | 7,021 |
| Adjustments | 0 | 0 | 0 | 0 | 0 |
| Adjusted net profit | 3,358 | 2,875 | 4,656 | 5,631 | 7,021 |

Balance Sheet

| Y/E 31 Mar (Rs mn) | FY21A | FY22A | FY23A | FY24E | FY25E |
|--------------------------|---------|---------|---------|---------|---------|
| Equity capital | 3,105 | 3,110 | 3,115 | 3,115 | 3,115 |
| Reserves & surplus | 34,481 | 37,378 | 42,546 | 47,614 | 53,933 |
| Net worth | 37,586 | 40,488 | 45,661 | 50,729 | 57,048 |
| Deposits | 297,039 | 346,917 | 412,389 | 482,908 | 562,587 |
| Borrowings | 44,823 | 40,818 | 41,181 | 47,358 | 53,515 |
| Other liab. & provisions | 16,574 | 19,702 | 24,427 | 42,678 | 52,288 |
| Total liab. & equities | 396,021 | 447,926 | 523,659 | 623,674 | 725,439 |
| Cash & bank balance | 30,393 | 40,908 | 23,684 | 39,214 | 45,793 |
| Investments | 84,137 | 90,507 | 125,825 | 142,656 | 160,492 |
| Advances | 259,592 | 290,958 | 343,807 | 405,693 | 476,689 |
| Fixed & Other assets | 21,899 | 25,554 | 30,342 | 36,111 | 42,465 |
| Total assets | 396,021 | 447,926 | 523,659 | 623,674 | 725,439 |
| Deposit growth (%) | (2.2) | 16.8 | 18.9 | 17.1 | 16.5 |
| Advances growth (%) | 2.4 | 12.1 | 18.2 | 18.0 | 17.5 |

Per Share

| Y/E 31 Mar (Rs) | FY21A | FY22A | FY23A | FY24E | FY25E |
|----------------------|-------|-------|-------|-------|-------|
| EPS | 10.8 | 9.3 | 15.0 | 18.1 | 22.5 |
| Dividend per share | 0.0 | 1.0 | 1.3 | 1.8 | 2.3 |
| Book value per share | 121.0 | 130.2 | 146.6 | 162.9 | 183.1 |

Valuations Ratios

| Y/E 31 Mar (x) | FY21A | FY22A | FY23A | FY24E | FY25E |
|--------------------|-------|-------|-------|-------|-------|
| P/E | 11.5 | 13.5 | 8.3 | 6.9 | 5.5 |
| P/BV | 1.0 | 1.0 | 0.8 | 0.8 | 0.7 |
| Dividend yield (%) | 0.0 | 0.8 | 1.0 | 1.5 | 1.8 |

DuPont Analysis

| Y/E 31 Mar (%) | FY21A | FY22A | FY23A | FY24E | FY25E |
|-------------------------|-------|-------|-------|-------|-------|
| Net interest income | 3.3 | 3.2 | 3.5 | 3.5 | 3.4 |
| Non-interest income | 1.2 | 1.1 | 0.8 | 0.9 | 0.9 |
| Operating expenses | 2.2 | 2.4 | 2.8 | 2.7 | 2.6 |
| Pre-provisioning profit | 2.3 | 1.9 | 1.6 | 1.7 | 1.8 |
| Provisions | 1.1 | 1.0 | 0.3 | 0.4 | 0.4 |
| PBT | 1.2 | 0.9 | 1.3 | 1.3 | 1.4 |
| Tax | 0.3 | 0.2 | 0.3 | 0.3 | 0.4 |
| ROA | 0.9 | 0.7 | 1.0 | 1.0 | 1.0 |
| Leverage (x) | 10.9 | 10.8 | 11.3 | 11.9 | 12.5 |
| ROE | 9.4 | 7.4 | 10.8 | 11.7 | 13.0 |

Ratio Analysis

| Y/E 31 Mar | FY21A | FY22A | FY23A | FY24E | FY25E |
|--|-------|--------|-------|-------|-------|
| YoY growth (%) | | | | | |
| Net interest income | 1.7 | 5.5 | 26.5 | 16.6 | 15.7 |
| Pre-provisioning profit | 19.3 | (11.3) | (1.3) | 21.7 | 26.2 |
| EPS | (0.8) | (14.5) | 61.7 | 20.9 | 24.7 |
| Profitability & Return ratios (%) | | | | | |
| Net interest margin | 3.5 | 3.4 | 3.8 | 3.7 | 3.7 |
| Fees / Avg. assets | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 |
| Cost-Income | 48.5 | 56.0 | 63.0 | 62.0 | 59.0 |
| ROE | 9.4 | 7.4 | 10.8 | 11.7 | 13.0 |
| ROA | 0.9 | 0.7 | 1.0 | 1.0 | 1.0 |
| Asset quality (%) | | | | | |
| GNPA | 4.0 | 4.2 | 3.2 | 2.6 | 2.3 |
| NNPA | 2.3 | 2.0 | 1.0 | 0.9 | 0.9 |
| Slippage ratio | 2.7 | 6.8 | 5.8 | 3.6 | 3.6 |
| Credit cost | 1.7 | 1.5 | 0.5 | 0.5 | 0.6 |
| Provision coverage | 42.9 | 53.6 | 67.2 | 63.1 | 63.1 |
| Ratios (%) | | | | | |
| Credit-Deposit | 87.4 | 83.9 | 83.4 | 84.0 | 84.7 |
| Investment-Deposit | 28.3 | 26.1 | 30.5 | 29.5 | 28.5 |
| CAR | 19.7 | 18.9 | 17.6 | 16.4 | 15.9 |
| Tier-1 | 15.5 | 15.8 | 15.2 | 14.3 | 13.8 |

Source: Company, BOBCAPS Research

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): DCB BANK (DCBB IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.